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The genetic contribution to the variation in human lifespan is ∼25%. Despite the large number of identified
disease-susceptibility loci, it is not known which loci influence population mortality. We performed a
genome-wide association meta-analysis of 7729 long-lived individuals of European descent (≥85 years) and
16 121 younger controls (<65 years) followed by replication in an additional set of 13 060 long-lived individuals
and61 156controls. In addition,weperformedasubsetanalysis in casesaged≥90years.Weobservedgenome-
wide significant association with longevity, as reflected by survival to ages beyond 90 years, at a novel locus,
rs2149954, on chromosome 5q33.3 (OR 5 1.10, P 5 1.74 3 1028). We also confirmed association of rs4420638
on chromosome 19q13.32 (OR 5 0.72, P 5 3.40 3 10236), representing the TOMM40/APOE/APOC1 locus. In a
prospective meta-analysis (n 5 34 103), the minor allele of rs2149954 (T) on chromosome 5q33.3 associates
with increased survival (HR 5 0.95, P 5 0.003). This allele has previously been reported to associate with low
blood pressure in middle age. Interestingly, the minor allele (T) associates with decreased cardiovascular
mortality risk, independentofbloodpressure.WereportonthefirstGWAS-identified longevity locusonchromo-
some 5q33.3 influencing survival in the general European population. Theminor allele of this locus associates
with lowbloodpressure inmiddle age, although the contributionof this allele to survivalmaybe lessdependent
onbloodpressure. Hence, thepleiotropicmechanismsbywhich this intragenic variation contributes to lifespan
regulation have to be elucidated.
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INTRODUCTION
Worldwide, human life expectancy has increased remarkably
over the last two centuries (1), although the healthy life expect-
ancy lags behind. Citizens of the European Union, for example,
spend only 75–80% of their lifespan in good health (2). Families
in which longevity clusters form an exception in this sense, by
showing beneficial or ‘youthful’ profiles for many metabolic
and immune-related parameters (3–7) and a low prevalence of
common diseases from middle age onwards (5,8,9). Therefore,
the genome of long-lived individuals is investigated to identify
variants that promote healthy aging and protect against
age-related disease. This is a major challenge because the
genetic component of lifespan variation in the population at
large has been estimated to be only 25% (10,11) and is
assumed to be determined by many, still uncharacterized,
genes (12,13). Genetic influences on human longevity are
expected to reflect longevity assurance mechanisms acting
across species (14), as well as more heterogeneous population-
specific effects. Although numerous genome-wide association
studies (GWAS) have successfully identified loci involved in
common, age-related diseases (15), the corresponding suscepti-
bility loci do not explain the genetic component of human lon-
gevity (16). GWAS for human longevity have thus far failed to
identify genome-wide significant loci, besides the well-known
TOMM40/APOE/APOC1 locus (17–19).
In this paper, we conducted a large genome-wide association
meta-analysis of human longevity in 14 studies with long-lived
cases (≥85 years) and younger controls (,65 years) from
European descent. In addition, we performed a subset analysis
in cases aged≥90 years. The novel longevity locus we identified
was tested for association with prospective (cause-specific) mor-
tality in a meta-analysis of 11 European cohorts and examined
for association with various metabolic traits that may explain
the mechanism by which the locus contributes to survival to
high ages.
RESULTS
Genome-wide association analysis
In order to identify novel loci involved in lifespan regulation, we
conducted a meta-analysis on GWAS data of 7729 long-lived
cases (≥85 years) and 16 121 younger controls (,65 years)
from 14 studies originating from 7 European countries (Supple-
mentary Material, Table S1). For each study, cases and controls
originated from the same country. Given the higher heritability
of longevity at older ages (11,20), we performed a subset ana-
lysis in which we compared cases aged ≥90 years (n ¼ 5406)
with 15 112 controls (,65 years) from the corresponding
control cohorts. Replication was performed in 13 060 cases aged
≥85 years (of which 7330 were ≥90 years) and 61 156 controls
from 6 additional studies, of which 3 originated from European
countries not represented in the discovery phase meta-analysis
(Supplementary Material, Table S1). Analysis of each study
was performed using a logistic regression-based method, and
results were adjusted for study-specific genomic inflation
factors (l) (Supplementary Material, Table S2). Meta-analysis
was performed on 2 480 356 (≥85 years) and 2 470 825 (≥90
years) imputed SNPs using a fixed-effect approach, and results
were further adjusted for the overall genomic inflation factor
(l ¼ 1.019) (Supplementary Material, Fig. S1). A flow chart
of the consecutive analysis steps is depicted in Figure 1.
The discovery phase meta-analyses of the cases aged ≥85
years (n ¼ 7729) showed genome-wide significant association
with survival into old age at one locus, the previously identified
TOMM40/APOE/APOC1 locus (17,21) (rs4420638 (G); odds
ratio (OR) ¼ 0.71, P ¼ 6.14 × 10219; Table 1). No gender-
dependent effects were observed in the sex-stratified analysis
of the cases aged ≥85 years (Supplementary Material, Table S4).
The discovery-phase meta-analysis of the cases aged ≥90
years (n ¼ 5406) showed a similar result, i.e. the TOMM40/
APOE/APOC1 locus was the only genome-wide significant
locus (OR ¼ 0.64, P ¼ 4.09 × 10221; Fig. 2 and Table 2). The
regional association plot and forest plot for the TOMM40/
APOE/APOC1 locus are depicted in Figures 3 and 4, respective-
ly. Although several SNPs on chromosome 19q13.32, which are
in moderate linkage disequilibrium (LD) with rs4420638, show
additional association with survival into old age, meta-analysis
conditional on rs4420638 showed no independent associations
among these SNPs (Supplementary Material, Fig S2 and Table S3).
Replication
In addition to the TOMM40/APOE/APOC1 locus, we found
eight loci that showed suggestive evidence for association in
the discovery-phase meta-analysis of cases aged ≥85 years
(P ≤ 1 × 1025; Table 1), whereas six additional SNPs met this
criterion in the meta-analysis of cases aged ≥90 years
(Table 2). The most or (when not successfully measured)
second most significant SNPs from these 14 loci and the
TOMM40/APOE/APOC1 locus were taken forward for replica-
tion in 13 060 cases aged ≥85 years (of which 7330 were also
≥90 years) and 61 156 controls from 6 additional studies. In
the joint analysis of the discovery and replication phase of the
cases aged ≥85 years (9 loci), the TOMM40/APOE/APOC1
locus remained the only genome-wide significant locus
(Table 1). The joint analysis of the discovery and replication
phase of the cases aged ≥90 years (12 loci), however, showed
an additional genome-wide significant locus, rs2149954 (T),
on chromosome 5q33.3 (OR ¼ 1.10, P ¼ 1.74 × 1028;
Table 2). Although the association of this SNP with survival
up to 85 years is not genome-wide significant (OR ¼ 1.07,
P ¼ 4.34 × 1026; Table 1), the locus likely affects survival
from middle age onwards. The regional association plot (based
on the discovery phase only) and forest plot of this locus are
depicted in Figures 3 and 4, respectively. Conditional analysis
of rs4420638 in the discovery phase studies showed that the as-
sociation of rs2149954 (T) with survival is independent of the
TOMM40/APOE/APOC1 locus (P ¼ 7.20 × 1026 instead of
P ¼ 5.98 × 1026 in the analysis of survival up to 85 years).
Prospective analysis
To determine the association of rs4420638 (TOMM40/APOE/
APOC1 locus) and rs2149954 (chromosome 5q33.3 locus)
with longitudinal survival, we performed a prospective
meta-analysis of the 2 SNPs in 34 103 individuals aged 30–
105 years from 11 different cohorts, of which 8582 had died
after a mean follow-up time ranging from 2.2 to 17.4 years
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(Supplementary Material, Table S5). Carriers of the minor allele
of rs4420638 (G) showed significantly higher all-cause mortal-
ity (hazard ratio (HR) ¼ 1.07, P ¼ 0.019), whereas carriers of
the minor allele of rs2149954 (T) demonstrated significantly
lower all-cause mortality (HR ¼ 0.95, P ¼ 0.003; Supplemen-
tary Material, Table S6).
Association with cardiovascular disease and blood pressure
To gain insight into the mechanism by which the chromosome
5q33.3 locus might promote human longevity, we analyzed the
cause-specific mortality of rs2149954. Carriers of the minor
allele of rs2149954 have a lower mortality risk for cardiovascu-
lar disease (CVD) (HR ¼ 0.86, P ¼ 0.004), which mainly
appeared to be caused by protection from stroke (HR ¼ 0.60,
P ¼ 2.27 × 1027). In addition, we observed an effect of this
SNP on non-CVD mortality (HR ¼ 0.86, P ¼ 0.002) (Supple-
mentary Material, Table S7). We also examined the Coronary
ARtery DIsease Genome-Wide Replication And Meta-Analysis
(CARDIoGRAM) GWAS (23), which showed a significant
association of rs2149954 with a decreased risk for coronary
artery disease (CAD) (OR ¼ 0.96, P ¼ 0.011) (Supplementary
Material, Table S8). In addition, two SNPs on chromosome
5q33.3 in high LD with rs2149954, rs9313772 (r2 ¼ 0.928)
and rs11953630 (r2 ¼ 0.854) have previously been reported to
associate with blood pressure and hypertension (24,25). As
expected, examining rs2149954 in the International Consortium
for Blood Pressure GWAS (24) showed a significant association
of the minor allele with lower diastolic (P ¼ 3.46 × 1025) and
systolic (P ¼ 6.55 × 1026) blood pressure (Supplementary
Figure 1. Flow chart of experimental work. The analysis in the cases aged ≥90 years is a subset analysis of the analysis in the cases aged ≥85 years. Twelve out of 14
studies used for the discovery phase analysis of cases aged≥85 years contained at least 100 cases over 90 years of age and were thus analyzed in the subset analysis of
cases aged ≥90 years.
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Table 1. Results of the discovery phase, replication phase and joint analysis of cases aged ≥85 years
Locus Lead SNP Chromosome Position Candidate/closest gene EA Analysis n EAF OR 95% CI P I2 (%) Phet
Cases Controls Cases Controls
1q43 rs1625040 1 235 213 002 MTR, RYR2 A Discovery 7729 16 121 0.170 0.150 1.16 1.09–1.23 3.36 × 1026
Replication 13 027 60 914 0.178 0.182 1.02 0.98–1.07 0.216
Joint 20 756 77 035 1.07 1.03–1.10 3.50 × 1024 31.0 0.093
2q24.3 rs6432832 2 166 079 072 CSRNP3 A Discovery 7729 16 121 0.344 0.321 1.12 1.07–1.17 2.79 × 1026
Replication 13 019 60 824 0.346 0.339 1.03 1.00–1.07 0.029
Joint 20 748 76 945 1.06 1.03–1.09 8.73 × 1026 0.0 0.467
4q27 rs13114426 4 120 942 533 PDE5A, MAD2L1 T Discovery 7729 16 121 0.387 0.405 0.90 0.87–0.95 2.20 × 1025
Replication 13 024 60 932 0.364 0.351 1.00 0.97–1.04 0.711
Joint 20 753 77 053 0.97 0.94–0.99 0.033 46.5 0.012
5q33.3 rs2149954 5 157 753 180 EBF1 T Discovery 7729 16 121 0.388 0.360 1.12 1.07–1.17 5.98 × 1026
Replication 12 973 60 262 0.365 0.352 1.04 1.01–1.07 0.013
Joint 20 702 76 383 1.07 1.04–1.09 4.34 × 1026 28.2 0.118
8q13.3 rs10957550a 8 72 457 142 EYA1 A Discovery 7727 16 093 0.268 0.285 0.88 0.84–0.93 3.61 × 1026
Replication 10 056 56 262 0.236 0.244 0.95 0.92–0.99 0.012
Joint 17 783 72 355 0.92 0.90–0.95 1.41 × 1026 29.4 0.130
10q23.33 rs4466755 10 96 622 243 CYP2C19, CYP2C9 T Discovery 7729 16 121 0.454 0.443 1.12 1.07–1.16 2.72 × 1026
Replication 13 051 61 105 0.488 0.508 0.98 0.95–1.01 0.129
Joint 20 780 77 226 1.03 1.00–1.05 0.161 65.6 2.15 × 1025
17q23.3 rs17760362 17 58 772 399 TANC2 A Discovery 7729 16 121 0.252 0.233 1.13 1.07–1.19 5.38 × 1026
Replication 13 007 60 679 0.252 0.249 1.04 1.00–1.07 0.033
Joint 20 736 76 800 1.07 1.04–1.10 1.56 × 1025 0.0 0.473
19q13.32 rs4420638a 19 50 114 786 APOE G Discovery 7728 16 111 0.157 0.195 0.71 0.67–0.77 6.14 × 10219
Replication 10 165 57 126 0.180 0.202 0.87 0.83–0.91 2.12 × 10212
Joint 17 893 73 237 0.82 0.79–0.85 2.33 × 10226 80.2 4.35 × 10210
20q13.2 rs8126377 20 51 590 254 TSHZ2, ZNF217 G Discovery 7532 15 902 0.059 0.069 0.79 0.71–0.87 1.35 × 1025
Replication 12 974 60 647 0.058 0.054 1.01 0.94–1.08 0.901
Joint 20 506 76 549 0.93 0.88–0.99 0.020 51.1 0.006
EA, effect allele; EAF, effect allele frequency after pooling the data of all analyzed individuals; OR, odds ratio for the effect allele; 95% CI, 95% confidence interval; I2, heterogeneity statistic; Phet, P-value for
heterogeneity.
aGenotyping of these SNPs with the Sequenom MassARRAY system for the replication phase was unsuccessful. The SNPs in bold overlap with Table 2.
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Material, Table S9). Despite the highly interesting association of
the minor allele of rs2149954 with low blood pressure and a
decreased risk for CAD, stroke and mortality, its association
with decreased all-cause mortality was not influenced by
blood pressure in two studies of participants aged ≥75 years
(PROSPER and Leiden 85-plus study Cohort II; Supplementary
Material, Table S10). This may indicate that at higher ages, this
locus influences longevity via pathways additional to those
involved in blood pressure regulation.
Phenotypic characterization and pathway analysis
In an attempt to identify the underlying mechanism by which this
novel longevity locus at chromosome 5q33.3 could influence
human longevity, we examined rs2149954 in the published
data of several large GWAS consortia for association with meta-
bolic traits in generally middle-aged individuals. None of the
investigated traits, i.e. 2 h glucose (OGTT), Hb1Ac, fasting
glucose, fasting insulin, insulin resistance (HOMA-IR), b-cell
activity (HOMA-B), total/HDL/LDL cholesterol, triglycerides
and type 2 diabetes (26–32), demonstrated evidence for associ-
ation (all P . 0.05) with rs2149954 (Supplementary Material,
Tables S8 and S9).
Gene set enrichment analysis (GSEA) of the meta-analysis
results of the discovery-phase analysis of survival aged ≥90
years using Meta-Analysis Gene-set Enrichment of variaNT
Associations (MAGENTA) (33), as well as examination of inter-
connectivity of implicated genes using Gene Relationships
Across Implicated Loci (GRAIL) (34) (Supplementary Material,
Fig. S3 and Table S11), provided no firm clues for potential path-
ways involved in human longevity.
Fine mapping and functional characterization
The newly identified longevity locus on chromosome 5q33.3 is
located in an intergenic region on chromosome 5q33.3, 302 kb
downstream of the EBF1 gene. To determine the functional
impact of this locus, we first identified the SNPs in LD with
rs2149954 (r2 ≥ 0.8) using the 1000 Genomes CEU Phase 1
data implemented in HaploReg v2 (http://www.broadinstitute.
org/mammals/haploreg/haploreg.php) (35). In total, we identi-
fied 25 SNPs, spanning a region of 22.3 kb (Supplementary
Material, Table S12). Subsequently, we examined the potential
effects of these SNPs on gene expression using several eQTL
databases. None of the SNPs showed an association with gene
expression in the various examined tissues, so it is still unclear
in which tissue(s) the locus exert its longevity-promoting
effect. We did, however, find some promising functional impli-
cation of this locus, i.e. the presence of multiple DNase I hyper-
sensitivity sites, transcription factor binding sites and enhancer
histone marks, by exploring ENCODE data using HaploReg
v2 (35) and RegulomeDB (http://www.regulomedb.org/) (36)
(Supplementary Material, Table S12). Very recently, a large
intergenic non-coding RNA (lincRNA), RP11-524N5.1, has
been annotated right on top of our locus. The poly(A) features
of this lincRNA are supported by PolyA-seq reads from liver,
muscle and testis. PhastCons 44-way alignment supports conser-
vation of the transcription start site (TSS), 3′ UTR and the third,
fifth and last exon of the lincRNA transcript (Fig. 5). The tran-
script does not align to the mouse genome, but orthologous tran-
scripts are found in other primate genome sequences, suggesting
that this is a primate-specific lincRNA.
DISCUSSION
We have performed the largest genome-wide association
meta-analysis for human longevity, in which a novel locus on
chromosome 5q33.3 associating with survival beyond 90 years
was identified.
The minor allele of rs2149954 (T) promotes human longevity
by reducing the risk of mortality owing to stroke and non-
cardiovascular causes. In addition, this allele has previously
been associated with low blood pressure, which may explain the
protection from CVD mortality risk in middle age. At ages
above 80 years, however, low SBP associates with increased mor-
tality (37,38). Hence, the observed blood pressure-independent
association of the minor allele with mortality ≥75 years may be
due to pleiotropic effects on other mortality-related clinical para-
meters. Examination of publically available data of several large
GWAS consortia for association of the locus with parameters
related to glucose and fat metabolism provided as yet no clues
for other potentially involved mechanisms.
Figure 2.Results of the discovery phase analysis. Manhattan plot presenting the
2log10 P-values from the discovery phase analysis of cases aged ≥85 years (A)
and ≥90 years (B). The loci that showed a genome-wide significant association
after the joint analysis of the discovery and replication phase (chromosome
19q13.32 and 5q33.3) are shown in red.
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Table 2. Results of the discovery phase, replication phase and joint analysis of cases aged ≥90 years
Locus Lead SNP Chromosome Position Candidate/closest gene EA Analysis n EAF OR 95% CI P I2 (%) Phet
Cases Controls Cases Controls
1q43 rs1625040 1 235 213 002 MTR, RYR2 A Discovery 5406 15 112 0.176 0.150 1.18 1.10–1.26 6.53 × 1026
Replication 7310 60 914 0.175 0.182 1.05 0.99–1.10 0.065
Joint 12 716 76 026 1.10 1.05–1.14 2.60 × 1025 9.3 0.343
4q22.2 rs4693331 4 94 760 609 GRID2 C Discovery 5406 15 112 0.416 0.444 0.89 0.84–0.93 6.63 × 1026
Replication 7267 60 324 0.449 0.440 1.03 0.99–1.07 0.095
Joint 12 673 75 436 0.97 0.94–1.00 0.139 61.3 3.51 × 1024
4q27 rs13114426 4 120 942 533 PDE5A, MAD2L1 T Discovery 5406 15 112 0.381 0.405 0.88 0.84–0.92 2.11 × 1026
Replication 7305 60 932 0.369 0.351 0.98 0.94–1.02 0.336
Joint 12 711 76 044 0.94 0.91–0.97 1.95 × 1024 32.5 0.090
5q33.3 rs2149954 5 157 753 180 EBF1 T Discovery 5406 15 112 0.396 0.360 1.14 1.09–1.21 1.85 × 1026
Replication 7298 60 262 0.374 0.352 1.07 1.03–1.12 5.98 × 1024
Joint 12 704 75 374 1.10 1.06–1.14 1.74 × 1028 28.5 0.125
7p14.2 rs11977641 7 36 761 949 AOAH, ELMO1 C Discovery 5406 15 112 0.062 0.076 0.78 0.70–0.87 7.31 × 1026
Replication 3049 4805 0.071 0.073 0.93 0.82–1.06 0.226
Joint 8455 19 917 0.84 0.77–0.91 1.57 × 1025 50.2 0.010
10q23.33 rs4466755 10 96 622 243 CYP2C19, CYP2C9 T Discovery 5406 15 112 0.455 0.445 1.13 1.07–1.18 1.30 × 1025
Replication 7326 61 105 0.477 0.508 0.98 0.94–1.02 0.208
Joint 12 732 76 217 1.03 1.00–1.07 0.087 55.4 0.002
12q15 rs11834614 12 67 197 344 MDM1, RAP1B C Discovery 5406 15 112 0.138 0.155 0.85 0.79–0.91 9.94 × 1026
Replication 7272 60 210 0.165 0.173 1.01 0.96–1.07 0.603
Joint 12 678 75 322 0.95 0.91–0.99 0.023 43.9 0.024
14q23.2 rs2784505 14 61 501 766 SYT16 G Discovery 5406 15 112 0.080 0.067 1.23 1.11–1.35 8.87 × 1025
Replication 7323 60 979 0.070 0.066 1.10 1.02–1.19 0.012
Joint 12 729 76 091 1.15 1.08–1.22 9.47 × 1026 28.3 0.127
17p13.1 rs940850 17 8 870 805 NTN1 T Discovery 5405 15 112 0.072 0.093 0.78 0.70–0.87 4.93 × 1026
Replication 7276 60 146 0.109 0.118 1.03 0.97–1.10 0.318
Joint 12 681 75 258 0.95 0.90–1.01 0.111 63.7 1.32 × 1024
17q23.2 rs2109265 17 58 307 001 MARCH10, TANC2 A Discovery 5406 15 112 0.443 0.420 1.13 1.08–1.19 3.34 × 1026
Replication 7307 60 672 0.453 0.465 1.01 0.97–1.05 0.671
Joint 12 713 75 784 1.06 1.02–1.09 0.001 34.7 0.074
19q13.32 rs4420638a 19 50 114 786 APOE G Discovery 5405 15 102 0.145 0.195 0.64 0.59–0.70 4.09 × 10221
Replication 4861 57 126 0.165 0.202 0.77 0.72–0.82 2.95 × 10218
Joint 10 266 72 228 0.72 0.68–0.76 3.40 × 10236 70.1 3.69 × 1025
20q13.2 rs8126377 20 51 590 254 TSHZ2, ZNF217 G Discovery 5209 14 893 0.057 0.068 0.75 0.66–0.85 3.38 × 1025
Replication 7278 60 647 0.063 0.054 1.04 0.95–1.13 0.309
Joint 12 487 75 540 0.94 0.87–1.00 0.117 58.1 0.001
EA, effect allele; EAF, effect allele frequency after pooling the data of all analyzed individuals; OR, odds ratio for the effect allele; 95% CI, 95% confidence interval; I2, heterogeneity statistic; Phet, P-value for
heterogeneity.
aGenotyping of this SNP with the Sequenom MassARRAY system for the replication phase was unsuccessful. The SNPs in bold overlap with Table 1.
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Rs2149954 is located in an intergenic region on chromosome
5q33.3 between CLINT1 and EBF1. The presence of several
regulatory elements in this region implies that transcription
factor binding and/or expression of (nearby) genes could be
influenced. The currently available eQTL databases did not
provide evidence for such effects, which might be due to the
limited tissue diversity of the databases. The effects of the
chromosome 5q33.3 locus on human longevity might be
exerted through the lincRNA, which has recently been annotated
right on top of our locus (RP11-524N5.1) and shows evidence for
expression in liver, muscle and testis. LincRNAs are involved in
chromatin modification and transcriptional regulation (39) and
seem to play a role in human disease (40). However, the newly
annotated lincRNA is not yet available in the large eQTL data-
bases, and the effect of SNPs in the chromosome 5q33.3 locus
on expression of this transcript still needs to be determined.
Hence, further functional studies are required to illuminate the
mechanism by which this locus influences human longevity.
Figure 3.Regional association plots for the chromosome 19q13.32 and 5q33.3 loci. Results of the discovery-phase analysis of chromosome 19q13.32 (A) and 5q33.3
(B) in cases aged ≥90 years, generated using LocusZoom (http://csg.sph.umich.edu/locuszoom/) (22). For the two SNPs taken forward to the replication phase
(rs4420638 and rs2149954), the results of the joint analysis are plotted. The color of the SNPs is based on the LD with the lead SNP (shown in purple). The blue
peaks represent the recombination rates based on HapMap Phase I+II CEU release 22 (hg18/build36), and the RefSeq genes in the region are shown in the lower panel.
Figure4.Forest plots for rs4420638 and rs2149954. Forest plots representing the odds ratios with 95% CI of rs4420638 (A) and rs2149954 (B) for the cohorts analyzed
in the discovery and replication phase (≥90 years). The size of the boxes represents the sample size of the cohort.
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GWAS has thus far not been a successful approach to identify
genome-wide significant hits for human longevity or mortality
besides the well-known TOMM40/APOE/APOC1 locus (17–19).
TheFOXO3A locus, for which the longevity effect is most promin-
ent in individuals aged ≥100 years (41), showed only moderate
evidence for association with survival ≥90 years in the discovery
phase of our GWAS (lowest P ¼ 1.35 × 1024 (rs1268161)).
Sebastiani and colleagues suggested that human longevity might
be explained by a signature consisting of 281 SNPs (42).
However, none of the SNPs (except the already known SNP
rs2075650 in TOMM40) was significant after adjustment for mul-
tiple testing (P, 1.78 × 1024 (0.05/281)). In addition, we did not
observe an enrichment of significant SNPs from their signature
in our data (l ¼ 1.004, Supplementary Material, Fig. S4).
Because the association of SNPs other than the TOMM40/
APOE/APOC1 locus could not be replicated in this, much
larger, GWAS, we have doubts that these signature SNPs are
indeed candidate SNPs influencing human longevity. Although
we detected merely one novel genome-wide significant locus,
the current GWAS had sufficient power, based on our results,
to detect lifespan-regulating loci with relatively small effects
(OR ,0.9 and .1.1).
The genetic component of human longevity is small (25%)
(10,11) and is assumed to be determined by many genes (12,13).
Furthermore, the genetic heterogeneity in ageing and lifespan
regulation is expected to be high, because individual genes
may contribute by a diversity of late acting deleterious stochastic
(germline) variation resulting in a genetic component that is hard
to disentangle (13). GWAS of complex late-onset diseases, such
as osteoarthritis and Alzheimer’s disease, with sample sizes
comparable to our current study (43–45), have identified more
loci compared with GWAS of longevity. This most likely reflects
the greater inherent complexity of the longevity trait, with its
diverse spectrum of biological pathways subject to intrinsic
and extrinsic (environmental) interactions. Hence, even larger
GWAS (.50 000 long-lived individuals) may be required to
identify additional longevity loci, preferably in the most strin-
gent phenotype, i.e. the oldest old.
As survival to ages ≥85 or 90 years is relatively common in
Western populations, the human longevity trait suffers from etio-
logical heterogeneity. Lifespan extension in the past generations
owing to non-genetic factors likely created phenocopies diluting
the genetic component of survival to ages ≥85 years. The
genetic contribution to survival to ages ≥100 years is higher but
will render smaller sample sizes for GWAS. This may explain
why the novel locus on chromosome 5q33.3 was only genome-
wide significant in the subset analysis of cases aged ≥90 years.
For the same reason, a large number of individuals from the
control groups (up to 50%, depending on the gender and year of
birth of the individuals and demography of the cohort) will live
to ages ≥85 years. In 2011, the mean life expectancy at age 65
in Europe was 21.3 years for women and 17.8 years for men
(http://epp.eurostat.ec.europa.eu/portal/page/portal/product_deta
ils/dataset?P_product_code=TSDDE210), which makes selec-
tion of proper controlsa challenging issue. The most ideal controls
would be individuals from the same birth cohort as the long-lived
cases that survived to the mean age of death of that birth cohort.
However, for most of these individuals there is no DNA available.
Alternatively, we selected controls that have not yet reached the
age of 65 years at inclusion to represent the frequency of variants
in the general population and minimize selection owing to mortal-
ity. Hence, the low contrast between cases and controls likely has
reduced our probability of identifying longevity loci.
In addition, there will be differences between case and control
cohorts that may have had an impact on our results. An example of
a potential confounder is smoking behavior, which was not ad-
equately measured in most elderly cohorts. However, none of
the SNPs that were previously associated with smoking behavior
in cohorts from European descent (according to the NHGRI
GWAS Catalog (http://www.genome.gov/gwastudies/)), namely
rs1051730, rs1329650 and rs4105144, show differences
between cases (≥85 years) and controls in the joint analysis of
the discovery and replication phase (all P. 0.05). We have to
note that these SNPs only explain a small proportion of the vari-
ance observed in smoking behavior. However, as the frequency
of these proxy SNPs for smoking behavior is similar between
cases and controls, we expect no obvious differences in
smoking behavior between the groups.
In conclusion, besides the previously implicated TOMM40/
APOE/APOC1 locus, we identified a novel locus on chromosome
5q33.3 that associates with survival beyond 90 years. Although
rs2149954 is associated with survival beyond 90 years at a
genome-wide significant level in our study, replication in addition-
al cohorts from European as well as non-European descent is war-
ranted. The minor allele of the lead SNP at this locus, rs2149954,
promotes human longevity in a prospective meta-analysis by low-
ering the risk of mortality owing to stroke and non-cardiovascular
causes. The locus harbors a lincRNA and is implicated in blood
pressure regulation, but the mechanism by which it influences lon-
gevity likely also involves other traits.
Figure 5.Chromosomal region around rs2149954. The region contains a lincRNA (RP11-524N5.1) for which the poly(A) features are supported by PolyA-seq reads
from liver, muscle and testis. RP11-524N5.1 is transcribed from the negative strand, and the phastCons 44-way alignment supports conservation of the TSS, 3′ UTR
and the third, fifth and last exon of the transcript. Rs2149954 and the 25 SNPs in high LD (r2 ≥ 0.8, according to HaploReg v2 (35)) are located in the first intron of
RP11-524N5.1.
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MATERIALS ANDMETHODS
Study populations
The discovery analysis was performed in 7729 cases that survived
to ages≥85 years (of which5406alsosurvived toages≥90years)
and 16 121 controls below 65 years at baseline, from 14 studies.
Replication was performed in 13 060 cases that survived to ages
≥85 years (of which 7330 also survived to ages ≥90 years) and
61 156 controls below 65 years at baseline, from 6 additional
studies. All individuals were of European descent. The details
of the discovery and replication studies can be found in Supple-
mentary Material, Tables S1 and S2. Some cohorts only provided
controls (GOYA, NTR, SU.VI.MAX, TwinsUK and WTCCC2)
or only cases (BELFAST, CEPH centenarian cohort, Danish lon-
gevity study I/II, Leiden 85-plus Study I/II and Newcastle 85+
Study), whereas others contained both (Calabria cohort,
deCODE, EGCUT, GEHA Study, German longevity study,
Leiden Longevity Study, Rotterdam Study I/II and TwinGene).
The names of the studies in the tables and figures are based on
the names of the cohorts containing the cases. The cases and con-
trols used for each study originated from the same country (Sup-
plementary Material, Table S1). The only exception is
BELFAST (Northern Ireland), for which we used controls from
the NTR (Netherlands). A check in the PROSPER study, which
includes individuals from Northern Ireland and the Netherlands,
showed that the allele frequencies in control individuals from
both countries are similar for our SNPs (data not shown). All par-
ticipants provided written informed consent, and the study was
approved by the relevant institutional review boards.
Genotyping, imputation and genome-wide
association analysis
All discovery studies were genotyped using Illumina genotyping
arrays, and pre-imputation quality control was performed for
each study separately. Imputation was performed using
IMPUTE or MACH with reference HapMap Phase I+II CEU
release 22 (hg18/build36). Further details about the genotyping,
quality control and imputation of each study are summarized in
Supplementary Material, Table S2.
Two replication studies (deCODE and the Danish longevity
study II) were also genotyped using Illumina genotyping
arrays and imputed using IMPUTE with reference HapMap
Phase I+II CEU release 22 (hg18/build36) (Danish longevity
study II) or deCODE software (deCODE). The other replication
studies were genotyped with the Sequenom MassARRAY
system using iPLEX Gold genotyping assays (Sequenom, San
Diego, CA, USA). More information about the studies used in
the replication phase can be found in Supplementary Material,
Tables S1 and S2. Of the 15 SNPs measured with the Sequenom
MassARRAY system, 13 were successfully genotyped in at least
95% of the samples and the average genotyping call rate was
99.80%. We also checked the concordance between the SNPs
measured with the Sequenom MassARRAY system and
(imputed) GWAS data of the Leiden 85-plus study I cases, and
the average concordance rate was 99.07%. The two SNPs that
were not successfully genotyped with the Sequenom MassAR-
RAY system (rs10957550 and rs4420368) were only analyzed
in the replication studies, which had imputed GWAS data avail-
able (deCODE and the Danish longevity study II).
All studies were analyzed separately using CC-assoc (https://
www.msbi.nl/dnn/Research/Genetics/Software/TestsforGWAS
inrelatedindividuals(cc_assoc).aspx), which is based on a modi-
fied version of the score test that takes into account imputation
uncertainty and familial relatedness (46). SNPs with a low
imputation quality (R2T ≤ 40) and a MAF of ≤1 or ≤5% (if
ncases , 200) were excluded from analysis in the discovery
phase. Adjustment for population stratification of the discovery
studies was performed by multiplying theR2T -adjusted variances
of the score statistic with the genomic inflation factor (lrange ¼
0.97 – 1.08, Supplementary Material, Table S2) of the study.
Meta-analyses
For the meta-analyses, a fixed-effect approach was used. Scores
and variances of the studies were combined to obtain a single
meta-statistic, which was adjusted using the genomic inflation
factor (l ¼ 1.019, discovery phase only) (Supplementary Ma-
terial, Fig. S1). For each analysis, we only used studies with at
least 100 cases (Supplementary Material, Table S1). P-values
,5 × 1028 were considered genome-wide significant (47). To
determine heterogeneity across the studies, the between-study
variance was calculated.
Conditional analysis
To ascertain independent signals at the chromosome 19q13.32
locus, we performed a meta-analysis conditional on rs4420638
in all studies used for the discovery phase analysis in cases
aged ≥85 years. The results are depicted in Supplementary
Material, Figure S2 and Table S3.
Sex-stratified analysis
Sex-stratified analysis of the cases aged≥85 years (nwomen¼ 5400
and nmen¼ 1865) was performed to investigate the presence of
gender-dependent associations. In addition, the 15 loci that
showed (suggestive) evidence for association with survival ≥85
and/or ≥90 years were tested for differences between sexes using
the formula: (bwomen − bmen)/
NameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMe
SE2women + SE2men
( )√
. The results
of this analysis are depicted in Supplementary Material, Table S4.
Prospective analysis
Prospective analysis of rs2149954 and rs4420638 was per-
formed using a Cox proportional hazards model adjusted for
age at baseline, sex and study-specific covariates. The details
about each of the analyzed cohorts are summarized in Supple-
mentary Material, Table S5.
Pathway analysis
For the pathway analysis, we used GSEA implemented
in MAGENTA (http://www.broadinstitute.org/mpg/magenta/)
(33). In short, each SNP is mapped to a gene considering a
window of 110 kb upstream and 40 kb downstream around the
genes. Subsequently, each gene is assigned a gene association
score based on the SNP with the lowest P-value, which is
mapped to that gene and this score is adjusted for confounding
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factors like gene size and the amount of SNPs per kb. Genes within
the HLA region were removed from analysis owing to high LD and
high gene density in that region. The GSEA algorithm tests for
over-representation of adjusted gene scores in a given pathway
using a pre-defined score rank cutoff (in our case, the 95th and
75th percentile). The generated statistic is then compared with
10 000–1 000 000 gene sets of identical size randomly sampled
from the genome to generate an empirical P-value for each path-
way. In total, 3216 pathways from Gene Ontology, PANTHER,
Ingenuity, KEGG, REACTOME and BIOCARTA were tested.
Pathways were considered significant if the FDR-adjusted
P-value (the 95th or 75th percentile) was ≤0.05.
To determine the relationship between loci associated with sur-
vival ≥90 years, we used GRAIL (http://www.broadinstitute.
org/mpg/grail/) (34). In short, this program maps SNPs to genes
and subsequently uses a text-mining algorithm on PubMed
abstracts to determine connections between these genes. Genes
from independent loci, which share informative words, receive
a high GRAIL similarity score and are more likely to be function-
ally related. As we only had a limited number of loci with at least
oneSNPwithaP-value≤1 × 1025 (n ¼ 12,Table2),wedecided
to perform GRAIL analysis on all loci with at least one SNP with a
P-value ≤1 × 1024 (n ¼ 65).
eQTL analysis
Todeterminewhether rs2149954orSNPs inLD(r2 ≥ 0.8basedon
1000 Genomes CEU Phase 1 data) influenced gene expression, we
searched several eQTL databases, namely (1) the Gutenberg Heart
Study database (GHS_Express) (48), which is based on expression
data of monocytes; (2) the Genotype-Tissue Expression (GTEx)
eQTL database (http://www.ncbi.nlm.nih.gov/gtex/GTEX2/gtex.
cgi), which is based on expression data of brain (cerebellum,
frontal cortex, temporal cortex and pons), liver and lymphoblastoid
cell lines; (3) the GENe Expression VARiation (Genevar) database
(http://www.sanger.ac.uk/resources/software/genevar/), which is
based on expression data of adipose tissue, fibroblasts, T cells,
skin and lymphoblastoid cell lines (49) and (4) the Blood eQTL
browser (http://genenetwork.nl/bloodeqtlbrowser/) (50).
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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